Alan Venook, MD: Re-initiating bevacizumab after multiple lines of treatment
Alan Venook, MD
Published Online:Jul 10, 2015
Following Diane's first-line recurrence, she is switched to FOLFIRI, and bevacizumab is continued.
Metastatic Colorectal Cancer: Part 2
Metastatic Colorectal Cancer: Part 1
Metastatic Colorectal Cancer: Part 2
Metastatic Colorectal Cancer: Part 1
Metastatic Colorectal Cancer: Part 2
Metastatic Colorectal Cancer: Part 1
Metastatic Colorectal Cancer: Part 2
Would you consider re-initiating bevacizumab in patients like Diane with multiple lines of treatment?
Bevacizumab could be considered at every decision point in this continuum of care.
CASE: Metastatic Colorectal Cancer (Part 2)
Following her first-line recurrence, Diane is switched to FOLFIRI, and bevacizumab is continued.- After 3 cycles, her CEA decreased to 19 ng/mL. The patient remained asymptomatic, and her hepatic lesions were stable
- CT scan revealed progression of multiple hepatic lesions, with several new nodules noted in the lung right upper lobe
- Biopsy of the lung and liver lesions was consistent with metastatic disease, and both samples were sent for mutational analysis
- Cetuximab infusion was delayed after the first cycle for 1 week due to rash
- After 4 cycles, she shows a response with her CEA decreasing to 32 ng/mL, and a reduction in hepatic lesions and stable lung lesions on CT.
- Her CT scan is consistent with progression of lung lesions
